December 25, 2017 | Israel’s Sheba Medical Center has been chosen by American biotechnology company BioMarin to conduct clinical trials and research of a breakthrough gene therapy product related to hemophilia. According to Gili Kenet, Director of the National Hemophilia Center at Sheba, the center will start enrolling patients in 2018, pending Ministry of Health approval. The gene therapy is said to be a “magic bullet” treatment for hemophilia A, a genetic blood disorder caused by missing or defective factor VIII, a clotting protein. The gene single therapy treatments use viruses to implant new genes into patient cells. An initial trial on nine patients has already been conducted by BioMarin. According to the report, all nine patients stopped using clotting factor drugs to treat their hemophilia and bleeding rates fell to almost zero. The National Hemophilia Center at Sheba Medical Center is an internationally recognized Hemophilia Training Center (HTC,) treating over 700 hemophiliacs a year.
[sharethis-inline-buttons]





December 24, 2017 | Israel’s 

December 24, 2017 | The Technion-Israel Institute of Technology in Haifa, dubbed “Israel’s MIT,” is wrapping up its inaugural 
December 21, 2017 | Israeli-South African philanthropist and entrepreneur Morris Kahn announced this week that he was donating an additional $1 million to the Genesis Prize, dubbed the “Jewish Nobel,” awarded to US-Israeli actress Natalie Portman for 2018. The Genesis Prize, established in 2012, recognizes individuals “who have attained excellence and international renown in their fields, and whose actions and achievements express a commitment to Jewish values, the Jewish community and the State of Israel.” Last month, Portman became the 5th Genesis Prize Laureate and announced she would give the money to organizations promoting women’s rights and equality in the educational, political and health spheres. Kahn 
December 21, 2017 | Israel’s mPrest, the software developer for Iron Dome’s anti-missile technology, announced together with the New York Power Authority that its system would be deployed in a number of utility plants across New York state, in addition to the Niagara Power Project where the tech has been in place for several months. NYPA and mPrest 











